BIOLASE announced that it is inviting clinicians and researchers from around the world to submit research proposals via the Research Grant Portal at biolase.com/researchgrants.
BIOLASE’s continued leadership and commitment to research and development in the dental field has been evident for over 30 years, resulting in hundreds of published articles, along with 302 issued and 31 pending patents on its technologies. This new research application portal is designed to help accelerate the submission, evaluation, and acceptance of research projects, while continuing to build upon the strong foundation of clinical evidence supporting BIOLASE laser technology.
In particular, BIOLASE is seeking studies in pediatric dentistry, endodontics, periodontics, implantology and photobiomodulation (PBM) to help further the advancement of minimally invasive laser technology in these fields.
“BIOLASE recognizes the importance of clinical research around the continued advancement of dental lasers and adoption of this breakthrough technology,” said BIOLASE President and CEO, John Beaver. “Our new Research Grant Portal will allow us to evaluate and accept high-quality research proposals from all over the world and continue to demonstrate how BIOLASE lasers provide biologically and clinically superior performance with a more comfortable patient experience and faster recovery times.”
To learn more about the grant application process and research topics of interest, please visit biolase.com/researchgrants.
The company is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications.
The company has sold over 43,300 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus, Waterlase Express, and laser dentistry, find the company online at biolase.com, Facebook at facebook.com/biolase, Twitter at twitter.com/biolaseinc, Instagram at instagram.com/waterlase_laserdentistry, and LinkedIn at linkedin.com/company/biolase.
BIOLASE, Waterlase and Waterlase iPlus are registered trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “continue,” “expect,” “believe,” “anticipate,” “estimate,” “predict,” “outlook,” “potential,” “plan,” “seek,” and similar expressions and variations or the negatives of these terms or other comparable terminology.
Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties that are described in the “Risk Factors” section of BIOLASE’s annual report filed on Form 10-K filed with the Securities and Exchange Commission.
Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.